Kevin Holden, Ph.D.

Kevin Holden, Ph.D. is CEO and co-founder of NV Therapeutics in Berkeley, California.

Kevin has over 20 years of experience in biotechnology startups with a focus on CRISPR genome engineering and synthetic biology. Between 2016 and 2024, he played a pivotal role in the growth and commercialization of Synthego, ultimately serving as Vice President of Science, overseeing scientific strategy and establishing key business and research partnerships.